Laddar...
Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies’ production. Recently, the US Food and Drug Administratio...
Sparad:
| I publikationen: | Patient Prefer Adherence |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6254654/ https://ncbi.nlm.nih.gov/pubmed/30538431 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S147163 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|